A tool to choose the best antibiotics for patients with drug-resistant tuberculosis
A clinical decision tool to optimize the selection of antibiotics for patients with rifampicin-resistant Tuberculosis
This study is working on a helpful tool for doctors to choose the best antibiotics for people with rifampicin-resistant tuberculosis, so they can get better treatment and avoid unnecessary side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10980109 on NIH RePORTER |
What this research studies
This research aims to create a clinical decision tool that helps healthcare providers select the most effective antibiotics for patients suffering from rifampicin-resistant tuberculosis (RR-TB). By utilizing drug susceptibility tests, the tool will guide treatment decisions, reducing the reliance on standardized regimens that may not be optimal for every patient. The approach focuses on improving patient outcomes by minimizing treatment failures and side effects associated with ineffective antibiotic use. The research will involve collaboration with healthcare settings to ensure the tool is practical and accessible.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rifampicin-resistant tuberculosis who require antibiotic treatment.
Not a fit: Patients who do not have drug-resistant tuberculosis or those who are not currently undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with drug-resistant tuberculosis, improving their chances of recovery.
How similar studies have performed: Other research has shown promise in developing decision-support tools for antibiotic selection, indicating that this approach could be effective.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Yaesoubi, Reza — Yale University
- Study coordinator: Yaesoubi, Reza
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.